mnda motor neurone disease association

virtual 33rd international symposium on ALS/MND

33rd international symposium on ALS/MND

virtual

6 - 9 December 2022

Programme

Organised by the Motor Neurone Disease Association
in co-operation with the
International Alliance of ALS/MND Associations

mnda motor neurone disease association

virtual 33rd international symposium on ALS/MND

Organiser of the Symposium:

mnda motor neurone disease association

Motor Neurone Disease Association
Francis Crick House, 6 Summerhouse Road
Moulton Park, Northampton NN3 6BJ

Held in co-operation with:

INTERNATIONAL ALLIANCE OF ALS/MND ASSOCIATIONS

The International Alliance of ALS/MND Associations
Email: alliance@als-mnd.org
Website: www.alsmndalliance.org

Foreword

Welcome to the 33rd annual symposium on ALS/MND, which for the third year in a row is being held online.

In the Harry Potter stories, Harry begins with no knowledge of his magical abilities, but as time goes on, he discovers how to wield them and use them to achieve his ends. Our understanding of ALS has followed a similar trajectory. We started with very little insight as to why ALS happens or how to intervene to stop it, but bit by bit we are making progress through science, building on our knowledge to develop new tools to find significant therapies. Initially, Harry could only use one spell at a time to defend his pals, but as his knowledge improved, he was able to simultaneously use many. Similarly, for many years we have had only one or two clinical trials to offer our patients at any one time, but now we have multiple trials, using varied approaches. Like Harry, we are achieving this progress with the help of many others, all working to the same goal – and we can see our friends and colleagues in this international symposium, bringing together researchers from across the globe.

Although the buzz and benefits of an in-person meeting cannot be replicated by a remote conference, we have done our best to mitigate and to capture that feeling as far as possible. A virtual symposium also means that people who would otherwise have difficulty attending are able to participate. This year, we showcase exciting advances in research through the entire pathway from discovery science to translation into meaningful treatments.

A major theme is neuroinflammation, its role in sporadic and familial ALS and the outcomes of therapies to tackle it. The design of clinical trials, and the outcome of a number of different approaches to treatment are also two big subjects. They are likely to feature more heavily over the next few years.

Genetics and other risk and modifier factors are always a major focus, but bioinformatics and AI are featuring more and more, as conventional methods for identifying genetic variants and environmental factors that influence ALS and ALS risk are exhausted.

Three more prominent and increasingly important topics this year are the role of metabolism in ALS, the role of RNA and protein processing, and the modelling of non-genetic ALS in the laboratory, something that has been challenging and largely missing from our armoury of research tools.

The International Symposium on ALS/MND is a major annual event for the ALS community, bringing scientists and clinical practitioners together to evidence the progress being made to cure ALS/MND. I wish you a very informative and enjoyable meeting.

Ammar Al-Chalabi
Programme Committee Chair

Tuesday 6 December 2022

Please note that all timings are GMT

SESSION 1

OPENING SESSION

Chairs: B Dickie (UK) A Al-Chalabi (UK)

13.45 – 13.50	Welcome – *B Dickie (UK) and A Al-Chalabi (UK)*	
13.50 – 14.35	The Stephen Hawking Memorial Lecture Introduction **C01** The contribution of aging to neurodegenerative disease	 *L Hawking (UK)* *F Gage (USA)*
14.35 – 14.45	Discussion/Questions	
14.45 – 14.55	International Alliance Humanitarian Award Forbes Norris and Humanitarian Awards	
14.55 – 15.10	IPG Award and winner's research presentation	
15.10 – 15.40	**ICEBREAKER SESSION**	

SESSION 2

CLINICAL TRIALS

Chairs: K Talbot (UK) B Dickie (UK)

1540 – 1600	**C02** Results from a randomized, double-blind, placebo-controlled trial of RNS60 in people with ALS	*E Pupillo (Italy)*
1600 – 1620	**C03** Modifying immune response and outcomes in ALS (MIROCALS): design and results of a phase 2b, double-blind randomized placebo-controlled trial of low dose interleukin-2 (ld IL2) in ALS	*G Bensimon (France)*
1620 – 1630	**C04** Evidence for a survival benefit in ALS with CNM-Au8 treatment: interim results from the RESCUE-ALS trial long-term open extension	*S Vucic (Australia)*
1630 – 1640	**C05** Evaluating efficacy and safety of Tofersen in adults with SOD1 ALS: Results from the Phase 3 VALOR trial and open label extension	*T Miller (USA)*
1640 – 1655	Discussion/Questions	
16.55 - 17.05	**BREAK**	

LIVE POSTER SESSION A

17.05 – 18.35 GMT

EPI-01 Frequency of mutations in C9orf72, SOD1, FUS, and TARDBP genes among amyotrophic lateral sclerosis cases: a review and meta-analysis
Ms Julie Barberio

EPI-02 Lessons Learned from Survival Modeling in an Expanded Access Protocol
Mr Alex Berger

EPI-03 The Canadian Neuromuscular Disease Registry: A national ALS registry for real world evidence
Dr Victoria Hodgkinson

EPI-04 Detection of spatial association between ALS and airborne lead (Pb) in Ohio
Dr Meifang Li

GEN-01 A case of an uncommon late onset of ALS associated with an undescribed SOD1 mutation
Dr Lucrezia Becattini

GEN-02 A novel mutation in ZFYVE26 gene (c.195-1G>A) in a young manaffected by spastic paraplegia
Dr Alessandro Bombaci

GEN-03 Genetic testing of people with early-onset MND in the West of Scotland
Dr Fraser Brown

GEN-04 The Role of Nicotinic Receptor Genes (CHRN) in Amyotrophic Lateral Sclerosis
Dr Filippo De Mattei

GEN-05 WITHDRAWN

GEN-06 Genetics in ALS: A change in attitude, no change in results.
Dr Ana Sanchez Fernandez

GEN-07 A Genome-wide association study on the New England and Ohio Amyotrophic Lateral Sclerosis Cohort
Mr Jiang Gui

GEN-08 Unraveling Clinico-Pathological Heterogeneity in Motor Neuron Diseases using Long-Read Sequencing
Ms Angita Jain

IVT-01 Superoxide Dismutase-1 Alters the Rate of Prion Protein Aggregation and Resulting Fibril Conformation
Miss Kamile Mikalauskaite

IVT-02 Investigating variants in NUP50 as risk factors for Amyotrophic Lateral Sclerosis
Ms Olga Roman

IVT-03 Effect of complement C3 inhibition in an iPSC-derived ALS neuromuscular junction model of neuroinflammation
Dr Scott Baver

IVT-04 Characterization of PPIA/EMMPRIN Pathway in Familial Models of Amyotrophic Lateral Sclerosis.
Mrs Gloria Nwamaka Edozie

IVT-05 Cellular function of hnRNP A1B, a longer HNRNPA1 isoform
Miss Mariana Llasera Ballester

IVT-06 The interactors of FUS
Dr Helena Motaln

IVV-01 Mapping PHD1-mediated neuroprotection in mutant SOD1 ALS mice at single-cell resolution.
Ms Christine Germeys

IVV-02 Sympathetic neurons are additional cell types affected in Amyotrophic Lateral Sclerosis
Mr Antonio Mazzaro

IVV-03 Novel insights on the role and therapeutic potential of Glycoprotein nonmetastatic melanoma protein B(Gpnmb) in Amyotrophic Lateral Sclerosis.
Dr Mauro Giuseppe Spatafora

IVV-04 Investigating ASO therapeutic strategies in targeting the ALS-causing FUSR521H variant using zebrafish
Mr Rampal Christian

IVV-05 Zebrafish TDP-43 knock-in CRISPR mutants develop a robust ALS-like phenotype independent of TDP-43 mislocalization
Mr Ziyaan Harji

IVV-06 Loss of C9orf72 induces neurodegeneration and autophagic deficits in a mouse model of TDP-43 proteinopathy
Ms Lilian Lin

IVV-07 Variants in NEMF, a ribosomal quality control protein, harbored in ALS patients cause motor phenotypes in mice
Ms Jennifer Stauffer

HCB-01 Intracellular transport and mitochondrial bioenergetics are reduced in iPS-derived motor neurons from ALS patients with TDP-43 mutations
Dr Ruxandra Dafinca

HCB-02 Formyl Peptide Receptor-Like 1 Depleted Monocytes in Amyotrophic Lateral Sclerosis
Mr Guy Hunt

HCB-03 Phosphorylation of Y526 FUS in FTD
Professor Boris Rogelj

HCB-04 ALS fibroblasts derived-exosomes increase wound healing
Mr Vincent Clément

HCB-05 Human motor neurons with mutations in TARDBP (TDP-43) derived from gene-edited iPSCs recapitulate features of ALS in vitro
Ms Sarah Lépine

HCB-06 A C-terminally truncated TDP-43 splice isoform exhibits neuronal specific cytoplasmic aggregation and contributes to TDP-43 pathology in ALS
Mr Marc Shenouda

BIO-01 WITHDRAWN

BIO-02 Creatinine Kinase-MB as a Complementary Biomarker in the Evaluation of Patients with Amyotrophic Lateral Sclerosis
Dr Sergio Castro-Gomez

BIO-03 Chitinase dysregulation predicts ALS disease aggressiveness and stems from multiple CNS populations
Ms Nayana Gaur

BIO-04 Blood Neutrophil-to-Lymphocyte ratio predict Survival in ALS patients
Miss Diana Monteiro Lopes

TST-01 Nicotinamide riboside, pterostilbene and ibudilast delay ALS progression in murine models
Professor Elena Obrador

TST-02 Combination therapy approaches for the treatment of Amyotrophic Lateral Sclerosis
Mrs Megan Baird

TST-03 How Much Do Patients Know About Basic Research? A Survey of Knowledge and Preferences Among People Living with ALS and Other Neurological Conditions
Professor Danielle Boyce

TST-04 Development of an UNC13A cryptic exon skipping antisense oligonucleotide as a treatment for ALS and FTD
Dr Wen-Hsuan Chang

TST-05 Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulator ATH-1105 is Neuroprotective in the TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis
Dr Kevin Church

TST-06 Discovery and Development of Inhibitors of 15-Lipoxygenase to Reduce Ferroptosis-Induced Injury for ALS and Neurodegenerative Diseases
Mr Jeff Trimmer

IMG-01 Motor Imagery in Amyotrophic Lateral Sclerosis: an fMRI study of postural control
Ms Malek Abidi

IMG-02 Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study
Mr Sergi Borrego - Écija

IMG-03 Brain-age predicts survival in ALS
Professor Andreas Hermann

CLT-01 Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Dr Jamie Timmons

CLT-02 Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS
Dr Jeffrey Bornstein

CLT-03 Clinical Trial Operations for the HEALEY ALS Platform Trial
Ms Marianne Chase

CLT-04 A variant-selective approach in C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD): Results from the FOCUS-C9 clinical trial
Dr Kenechi Ejebe

CLT-05 Longitudinal comparison of the self-entry amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-RSE) and rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis
Dr Stephen Johnson

CLT-06 Wearable and smartphone devices can track ALS disease progression and may serve as novel clinical trial outcome measures
Dr Marta Karas

CLT-07 Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Mr Philip Green

CLT-08 QRL-201-01 - A multi-center, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis
Ms Kristiana Salmon

CLT-09 The Integrated Stress Response is modulated by eIF2B agonist DNL343: Results from Preclinical, Phase 1 Healthy Subject and Interim Phase 1b ALS Patient Studies
Dr Linus Sun

DSP-01 WITHDRAWN

DSP-02 Changes in objective temporal speech measures during ALS-FRS-R plateau phases
Dr Liziane Bouvier

DSP-03 Longitudinal Changes to Communicative Participation in ALS
Dr Kathryn Connaghan

DSP-04 Approaches to Evaluating Speech Severity of Remote Speech Recordings
Dr Abigail Haenssler

DSP-05 The ALS CURE Project 2022 Roadmap to Cure ALS : an approach to enable international research collaboration
Mr Mike Piscotty

DSP-06 Exploring the analytical validity of the Winterlight assessment app – a novel, home-based speech assessment tool – in ALS
Dr Leif Simmatis

COG-01 Making Sense:An online Meaning Centred Psychological intervention for individuals with MND
Mrs Sandra de Moree

COG-02 Clinicoanatomical substrates of selfish behaviour in amyotrophic lateral sclerosis – an observational cohort study
Professor Dorothee Lule

COG-03 A novel EEG paradigm to quantify the cortical network dysfunction underpinning verbal fluency impairments in ALS
Ms Serena Plaitano

CMS-01 IMPACT ALS EUROPE SURVEY - People living with ALS in Europe
Miss Éilís Conroy

CMS-02Understanding family experiences of inherited MND: qualitative interview study and new resource on healthtalk.org
Miss Jade Howard

CMS-03 A multi-centre evaluation of post-gastrostomy management in motor neuron disease (PostGas) to understand why patients often experience poor nutritional outcomes following placement of a feeding tube
Miss Lucy Musson

CMS-04 Critical Resources for Underserved Veterans with ALS - Combating Deserts of Care
Mrs Mandi Bailey

CMS-05 CBAS: Ongoing Data Collection & Validation
Professor Laura Ball

CMS-06 At-Home Telespirometry (AHT) In Amyotrophic Lateral Sclerosis (ALS) Implementation Science: Evidence-Based Development of Vital Capacity (VC) Measurement Frequency Algorithm for Clinical Testing
Professor Benjamin Rix Brooks

CMS-07 WITHDRAWN

CMS-08 Proximity to UCSF ALS Satellite Clinics Increases Rural Patient Access and Clinic Visit Frequency, But Disparities Remain
Dr Jill Goslinga

CMS-09 Equipment for Living with ALS: Results from the ALS Focus Mobility Survey
Dr Sarah Parvanta

Wednesday 7 December 2022

LIVE POSTER SESSION B

12.15 – 13.45 GMT

EPI-05 A Review of the Efficacy of Edaravone and the Factors That Influence its Response in Patients With Amyotrophic Lateral Sclerosis
Miss Maleesha Jayasinghe

EPI-06 WITHDRAWN

EPI-07 'He's been brave for me and I've been brave for him' meaning in life and personal satisfaction as positive aspects for ALS caregivers – A longitudinal mixed methods analysis
Miss Éilís Conroy

EPI-08 Exposure to electromagnetic fields does not modify neither the onset age nor the disease progression in ALS patients
Dr Margherita Daviddi

GEN-09 WITHDRAWN

GEN-10 Study into a possible common founder effect for the SOD1 p.V48A mutation amongst Malaysian Chinese and Mainland Chinese ALS patients
Miss Suzanna Edgar

GEN-11 Comprehensive genetic study of genes that alter NAD+ levels in Australian sporadic amyotrophic lateral sclerosis
Dr Jennifer Fifita

GEN-12 Prediction of pathogenicity of ALS-causing gene missense variants using structural information predicted by AlphaFold2
Mr Yuya Hatano

GEN-13 Sex-stratified analysis of ~133k samples identifies novel associations with Amyotrophic Lateral Sclerosis
Dr Ross Byrne

GEN-14 Whole-genome sequencing reveals that variants in the IL18RAP 3'UTR protect against ALS
Dr Chen Eitan

GEN-15 Genetic analysis of ALS in Russia
Miss Alina Korbut

GEN-16 Genome-wide association study of rare variants in ERV-elements of ALS patients: age at onset of ALS may be regulated by MLT1B ERV-element.
Dr Alexey Shatunov

IVT-07 Dysregulation of SFPQ in motor neuron disease
Dr Alison Hogan

IVT-08 Dysregulation of cellular energy metabolism and axonal transport in TDP-43 M337V mESC-derived motor neurons
Miss Emily Carroll

IVT-09 TBK1 kinase inhibition is associated with cell autonomous microglial dysfunction
Miss Uroosa Chughtai

IVT-10 Mechanistic insights into the cause of DNA damage accumulation in cells bearing TDP-43 and FUS cytoplasmic inclusions
Miss Stefania Modafferi

IVT-11 Characterization of iPSC-motoneurons from a HSP patient with a novel mutation in KIF5A N-terminal region
Dr Serena Santangelo

IVV-08 Synergistic activity of a nerve-muscle, multimodal combination therapy in mutant SOD1 mice
Professor Peter Crouch

IVV-09 Longer telomeres are present in a mouse model of amyotrophic lateral sclerosis displaying TDP-43 pathological features
Dr Anna Konopka

IVV-10 The Serum Response Factor (SRF) regulates motoneuron vulnerability in ALS through the regulation of autophagy flux
Miss Natalie Yashoda Dikwella

IVV-11 The increased expression of neuregulin-1 type III in neurons in double transgenic mice does not improve ALS-related pathology or extend the lifespan of SOD1G93A mice
Dr Sara Hernández

IVV-12 Exploring the clinical relevance of compound muscle action potential data in the SOD1G93A mouse
Mr Scott McKinnon

IVV-13 Axonal transport of diverse cargoes in fast and slow α-motor neurons in multiple ALS mice
Dr Andrew Tosolini

HCB-07 Evaluating models of Motor Neuron Disease molecule by molecule.
Dr Dezerae Cox

HCB-08 Immunological characterization of spinal cord organoids derived from sALS patients
Dr Matteo Bordoni

HCB-09 ALS/FTD-associated C9orf72 C4G2 repeat RNA binds to FARS protein and affect the rate of phenylalanine-tRNA aminoacylation
Ms Urša Čerček

HCB-10 RNA G-quadruplex structures regulate stress granule dynamics
Mr Yehuda-Matan Danino

HCB-11 Towards a quantitative protein atlas of human iMN and their extracellular vesicles
Dr Raquel Mesquita-Ribeiro

HCB-12 HuD gain-of-function leads to disruption of the neuromuscular junction and apoptosis in FUS-ALS iPSC-derived muscle-nerve co-cultures
Professor Alessandro Rosa

HCB-13 WITHDRAWN

BIO-05 The first evaluation of calretinin in the spinal axons encompassed in anterolateral funiculi outside the corticospinal tract and cerebrospinal fluids of ALS patients
Dr Shintaro Hyashi

BIO-06 WITHDRAWN

BIO-07 Benchmarking Proteome of Extracellular Vesicles From Plasma Of fALS-Associated SOD1 Mutant Patients And SOD1 Mutant Healthy Controls
Dr Aslihan Gunel

BIO-08 First evidence of altered Gas6-Axl signaling and correlation between sAXL blood levels and clinical decline in ALS
Dr Marco Peviani

BIO-09 Premorbid primary care blood biomarker alterations support a metabolic prodrome in amyotrophic lateral sclerosis
Dr Alexander Thompson

TST-07 Inhibition of glucosylceramides improves cell viability and TDP-43 mislocalisation in ALS iPSC-LMNs
Miss Leanne Jiang

TST-08 Investigating novel gene therapy approaches to target RAN-translation of pathological C9ORF72 repeat transcripts in ALS/FTD
Miss Bridget Benson

TST-09 The identification of SCFV'S that bind to TDP-43 and prevent its induced aggregation as a potential therapy for ALS
Professor Hélène Blasco

TST-10 The feeding behaviour of Amyotrophic Lateral Sclerosis mousemodels is modulated by the Ca2+-activated KCa3.1 channels
Mrs Germana Cocozza

TST-11 Novel functionalized nanoparticles targeted to 18KDa translocator protein (TSPO) to track and modulate neuroinflammation in animal models of familial Amyotrophic Lateral Sclerosis
Mr Andrea Gazzano

TST-12 Effects of therapeutic hypothermia in an animal model of Amyotrophic Lateral Sclerosis.
Dr Laura Pasetto

TST-13 VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic Lateral Sclerosis
Dr Andreia Duarte

IMG-04 WITHDRAWN

IMG-05 A monocentric case series of Hirayama's disease: clinical, neurophysiological, imaging features and differences with Amyotrophic Lateral Sclerosis.
Dr Sara Cabras

IMG-06 Clinical utility of structural and diffusion brainstem analysis in predicting bulbar and respiratory dysfunction.
Dr Mohammed Khamaysa

CLT-10 EPI-589 early Phase 2 Investigator-initiated Clinical trial for ALS (EPIC-ALS)
Dr Shotaro Haji

CLT-11 TUDCA as disease modifier for ALS: time will tell truth
Dr Antoniangela Cocco

CLT-12 First in human phase 1/2a study evaluating the safety and efficacy of the Akt activator, IPL344 in ALS (NCT03652805, NCT03755167).
Professor Marc Gotkine

CLT-13 Design of an international, phase 3, randomized, placebo-controlled trial with daily oral edaravone (fnp122) in als: the adore study
Dr Ruben van Eijk

CLT-14 Remote monitoring of accelerometry for amyotrophic lateral sclerosis detects differences in disease progression and survival
Mr JWJ van Unnik

CLT-15 Shifting the Paradigm – PrimeC: A Potential Disease-Modifying Treatment for ALS Driven by Novel Biomarkers Measuring Mechanism of Action
Dr Shiran Zimri

DSP-07 WITHDRAWN

DSP-08 Protein structure based FUS mutational subtypes are linked with subcellular mislocalization and age at onset in amyotrophic lateral sclerosis
Mr Wanli Yang

DSP-09 When rare gets rarer: five reports of association between ALS and other uncommon conditions from a large cohort of patients in Central Italy
Dr Francesca Bianchi

DSP-10 A patients with ALS and TBK1 loss of function mutation: a case report.
Dr Lorenzo Fontanelli

DSP-11 Phenotype-specific gene expression patterns identification through transcriptome-phenotype investigation in unmutated sporadic ALS patients
Dr Maria Garofalo

DSP-12 Traditional Methods of Quantifying Upper Limb Function in ALS and the Need for Objective Solutions
Mr Conor Hayden

DSP-13 Defining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD
Dr Caroline McHutchison

DSP-14 Relevance of respiratory tests in determining respiratory involvement in ALS
Dr Susana Pinto

COG-04 Premorbid psychological resilience is protective against cognitive deterioration in motor neuron diseases
Dr Pilar Maria Ferraro

COG-05 Quantifying network dysfunction underpinning social cognition impairments in ALS with EEG
Dr Roisin McMackin

COG-06 Experiences, coping strategies and support needs of family caregivers of ALS-patients post-bereavement
Mrs Sabina Pujic

COG-07 Cognition in the Course of ALS – a Meta-Analysis
Mrs Julia Finsel

CMS-10 Utility of three-dimensional (3D) motion capture in monitoring disease progression in amyotrophic lateral sclerosis (ALS)
Ms Akiko Goto

CMS-11 Robot-assisted training using HAL ameliorates gait ability in patients with amyotrophic lateral sclerosis
Miss Harumi Morioka

CMS-12 Satisfaction with health-associated support system in Germany and Poland from the perspective of patients with amyotrophic lateral sclerosis, their caregivers and physicians
Dr Krzysztof Barć

CMS-13 Paraneoplastic motor neuron disease with anti-CV2 antibodies
Sra Maria Dolores Calabria Gallego

CMS-14 The role of maximal voluntary ventilation in evaluating respiratory function of ALS patients
Professor Mamede Alves De Carvalho

CMS-15 Making her end of life her own: further reflections on supporting a loved one with motor neurone disease
Dr Denise Harris

CMS-16 Feasibility and acceptability of the real-world implementation of Telehealth in Motor Neuron Disease (TiM) service in two specialist MND centres.
Dr Liam Knox

CMS-17 'Gastrostomy Tube: Is it for Me?' Development and pilot testing of a web-based patient decision aid for people with motor neurone disease considering a gastrostomy tube (DiAMoND Study)
Dr Sally Wheelwright

13.45 - 14.00 BREAK

SESSION 3

METABOLISM

Chairs: B Dickie (UK) A Al-Chalabi (UK)

PARALLEL SESSION

14.00 – 14.25	**C06** Investigating the role of hypermetabolism in ALS	*S Ngo (Australia)*
14.25 – 14.40	**C07** Dysregulated energy metabolism related to worse prognosis in ALS	*J He (China)*
14.40 – 14.55	**C08** An 18F-FDG-PET study exploring the metabolic signature of pure bulbar and pure spinal ALS	*F Di Pede (Italy)*
14.55 – 15.10	Discussion/Questions	

14.00 – 14.45 Sponsored Parallel Session 1 (non-CME)

15.10 – 15.40 **NETWORKING EVENT**

SESSION 4

CELL BASED MODELS

Chairs: G Tyzak (UK) N Cole (UK)

PARALLEL SESSION

15.40 – 16.05	**C09** iPSC-derived models for compound screening and the identification of new therapeutic strategies	*K Roet (USA)*
16.05 – 16.20	**C10** Sporadic ALS motor neurons recapitulate neuronal vulnerability	*B Turner (Australia)*
16.20 – 16.35	**C11**Reduced C9orf72 expression exacerbates poly-GR toxicity in patient iPSC-derived motor neurons	*T Dane (USA)*
16.35 – 16.50	Discussion/Questions	

15.40 – 16.25 Sponsored Parallel Session 2 (non-CME)

16.50 – 17.05 **BREAK**

SESSION 5

DISEASE PRESENTATION AND RISK

Chairs: A Thompson (UK) A Al-Chalabi (UK)

PARALLEL SESSION

17.05 – 17.25	**C12** Identifying risk factors using Mendelian Randomization	*G Davey Smith (UK)*
17.25 – 17.45	**C13** Traumatic Brain Injury as a risk factor for neurodegenerative disease	*C Tartaglia (Canada)*
17.45 – 18.05	**C14** Mild motor impairment and prodromal markers	*M Benatar (USA)*
18.05 – 18.20	Discussion/Questions	

17.05 – 17.50
Sponsored Parallel Session 3 (non-CME)

Gabriel Benois

Chris Montgomery

Thursday 8 December 2022

SESSION 6

GENETICS AND GENOMICS

Chairs: C Vance (UK) A Al-Chalabi (UK)

PARALLEL SESSION

14.00 – 14.45 Sponsored Parallel Session 4 (non-CME)

14.00 – 14.25	**C15** Decoding gene regulatory networks in ALS	*J Kirby (UK)*
14.25 – 14.40	**C16** Unsupervised hierarchical clustering of postmortem motor cortex expression data identifies distinct molecular phenotypes which replicate the major mechanisms of ALS pathogenesis	*H Marriott (UK)*
14.40 – 14.55	**C17** Interactions between genetic modifiers of survival in ALS: a population based study	*A Chio (Italy)*
14.55 – 15.10	Discussion/Questions	

15.10 – 15.25 **BREAK**

SESSION 7

RNA AND PROTEIN PROCESSING

Chairs: M Hallegger (UK) N Cole (UK)

15.25 – 15.50	**C18** Protein chaperones as a therapeutic target for ALS	*H Durham (Canada)*
15.50 – 16.15	**C19** MicroRNA dysregulation in motor neuron disease	*E Hornstein (Israel)*
16.15 – 16.30	**C20** Diminished miRNA activity is associated with aberrant cytoplasmic intron retention in ALS pathogenesis	*H Crerar (UK)*
16.30 – 16.45	Discussion/Questions	

16.45 – 17.00 **BREAK**

LIVE POSTER SESSION C

17.00 – 18.30 GMT

EPI-09 Kidney Function (eGFR MDRD) in ALS Patients
Mr Matteo Locatelli

EPI-10 Poliomyelitis Survivors in the Time of a Covid-19 Pandemic
Miss Jeyce Nogueira

EPI-11 Estimates of C9orf72 Statistics drawn from prior publications, including estimated Life Expectancy for Genetic Carriers, Estimated Incidence of C9orf72 ALS and FTD Diagnoses, Estimated Genetic Carrier and At Risk Population and others.
Ms Jean Swidler

EPI-12 Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis
Dr Nimish Thakore

GEN-17 Fine-tuning a molecular diagnosis algorithm for patients with ALS and FTD
Dr Daniel Borrego Hernández

GEN-18 Exploring the role of HERV-K integrations in amyotrophic lateral sclerosis
Mr Harry Bowles

GEN-19 SOD1 D91A variant in the southernmost tip of Europe: a heterozygous ALS patient resident on the island of Gozo
Professor Ruben Cauchi

GEN-20 Allele genotype of a SINE-VNTR-Alu (SVA) retrotransposon correlates with differential gene expression at the MAPT locus
Mr Alexander Fröhlich

GEN-21 Utilising genetic data and quality of life metrics within the TONiC initiative to better predict patient outcome, progression and severity in ALS
Dr Ben Middlehurst

GEN-22 Targeted long-read sequencing of C9orf72 in blood of patients with ALS
Mr Evan Udine

GEN-23 WITHDRAWN

IVT-12 iPSC-derived motor and sensory neurons have distinct molecular profiles but share axonal vulnerability due to the C9orf72 hexanucleotide repeat expansion
Dr Jakub Scaber

IVT-13 Characterization of PPIA/EMMPRIN pathway in the peripheral nervous system of SOD1G93A model of Amyotrophic Lateral Sclerosis
Miss Marion Boyer

IVT-14 Using PRMT Inhibition to Abrogate Dipeptide Repeat Protein Toxicity in C9orf72-Mediated ALS: A Proteomics Assessment of Post-Translational Modifications
Ms Anna Gill

IVT-15 Traumatic injury exacerbates neuropathology in C9orf72 ALS/FTD motor neurons
Mr. Eric Martin

IVT-16 Effects of arginine methylation state on the subcellular localization of C9orf72 repeat expansion associated toxic dipeptide repeat proteins.
Ms Kaly Mueller

IVV-14 Cytoplasmic accumulation of FUS in adult neurons prevents establishment of social memory but preserves motor function
Dr Luc Dupuis

IVV-15 Imaging the spinal cord neurodegeneration of the TDP-43-A315T ALS mouse model: relationship between MRI and TDP-43 aggregates
Dr Débora Lanznaster

IVV-16 Alteration of the neuromuscular junction and modifications of muscle metabolism in response to neuron-restricted expression of the CHMP2BINTRON5 mutant in a mouse model of ALS-FTD syndrome
Dr Frederique Rene

IVV-17 Development of a zebrafish Stathmin-2 (STMN2) knockout model
Mr Tyler Gurberg

IVV-18 C57BL/6J-Ighmbp2EM6 displays respiratory and neuromuscular characteristics of very severe SMARD1
Miss Sarah Holbrook

IVV-19 Is ALS onset accelerated by Chloroviruses and delayed by antiviral immune responses?
Dr Gary Pattee

HCB-14 Alterations in the interactome of wild-type TDP-43 and mutant TDP-43 lacking nuclear localization signal
Ms Jerneja Nimac

HCB-15 Crosstalk between NEAT1_1 lncRNA and TDP-43 in ALS
Dr Tatyana Shelkovnikova

HCB-16 Dynamic Expression Profiles of Stressed iPSC-MNs from C9orf72-ALS Patients by Translating Ribosome Affinity Purification (TRAP)
Dr Yinyan Xu

HCB-17 Discovery of novel small molecule Cu(II) complexes using a genome edited iPSc-based phenotypic screening platform
Dr Kyle Denton

HCB-18 SIRT1 is associated with the alleviation of DPR pathology in C9orf72-associated disease
Ms Sophie Imhof

HCB-19 Stabilizing Microtubules Rescues Disrupted Nucleocytoplasmic Transport in Loss-of-Function Models of the ALS Gene NEK1
Dr Jacob Mann

HCB-20 Proteome-Wide Degradation Dynamics in ALS SOD1 Patient Neurons Reveals Disrupted VCP Homeostasis
Dr Konstantinos Tsioras

BIO-10 Integrated deep proteomics of cerebrospinal fluid for biomarker identification in ALS
Dr Elizabeth Dellar

BIO-11 Inflammasome genes expression as biomarkers in ALS and FTD patients
Miss Laura Expósito Blázquez

BIO-12 Characterisation of the role of the gut-brain axis in the pathophysiology and progression of motor neuron disease
Miss Iman Geelani Khwaja

BIO-13 Erythrocyte membrane properties in patients with ALS
Dr Ana Catarina Pronto Laborinho

BIO-14 WITHDRAWN

TST-14 A Retrospective Analysis of Dietetic Input Received by Patients with Motor Neurone Disease (MND) and Dietetic Workload when Caring for the MND Population across Varied National Health Service Settings 2019/2020
Ms Justyna Reinert

TST-15 Engrailed-1 homeoprotein is a non-cell autonomous neurotrophic factor

for motoneurons
Dr Stephanie Elizabeth Vargas Abonce

TST-16 QRL-201: A Stathmin-2 splice-switching antisense oligonucleotide for the treatment of ALS
Ms Taylor Gray

TST-17 Preclinical Characterization of Prosetin, A Novel, Brain-Penetrant, Clinical-Stage MAP4K Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
Dr Emily Lowry

TST-18 Targeting the NFkb pathway as a therapeutic strategy for stabilizing dendritic structure in an ALS-FUS mouse model
Mrs Mari Carmen Pelaez

TST-19 Hydrogen Peroxide and Amyotrophic Lateral Sclerosis: From Biochemistry to Pathophysiology
Mr Nitesh Sanghai

TST-20 Targeting neuregulin1 on microglia to slow or stop ALS
Professor Fei Song

TST-21 Development of TDP-43 inhibitors for the treatment of ALS, FTD, and Alzheimer's disease
Dr Chengliang Zhang

IMG-07 Dysfunction of cortical inhibitory interneurons In Amyotrophic Lateral Sclerosis
Mrs Cristina Benetton

IMG-08 Role of brain 18Fluorodeoxyglucose-Positron-Emission Tomography as survival predictor in Amyotrophic Lateral Sclerosis
Dr Antonio Canosa

IMG-09 Brain sensorimotor integration after focal muscle-tendon vibrations in amyotrophic lateral sclerosis
Mr Arnaud Preuilh

CLT-16 Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study
Dr James Berry

CLT-17 Using Active Digital Phenotyping to Quantify Function and Speech in Amyotrophic Lateral Sclerosis (ALS)
Dr Katherine Burke

CLT-18 The HEALEY ALS Platform Trial: Results of Regimens A-D
Dr Merit Cudkowicz

CLT-19 Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results
Dr Angela Genge

CLT-20 Operationalizing meaningful participant engagement in ALS research: Early lessons from CAPTURE ALS
Dr Wendy Johnston

CLT-21 Using asynchronous online focus groups to improve access to research for people affected by amyotrophic lateral sclerosis (ALS): A methodological exploration
Ms Westerly Luth

CLT-22 Phase 3b, Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Oral Edaravone Administered Over 48 Weeks in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A02)
Dr Alejandro Salah

CLT-23 ENCALS Predictive Survival Model in FORTITUDE-ALS
Dr Tyrell Simkins

CLT-24 Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Professor Leonard van den Berg

DSP-15 WITHDRAWN

DSP-16 Interaction of gender and onset site in the progression of ALS - A multivariate disease modelling approach
Ms Juliette Ortholand

DSP-17 Evaluating nQ as an objective biomarker to assess fine motor impairment in people with ALS
Alison P. Clark

DSP-18 Wearable sensors for tracking activity patterns in patients with motor neuron disease
Dr Andrew Geronimo

DSP-19 Cepstral/Spectral Measures of Dysphonia in Amyotrophic Lateral Sclerosis
Mr Marc Maffei

DSP-20 ALS Precision Medicine Program: Cohort Overview of a Comprehensive Natural History and Translational Research Study for the Identifcation of ALS Therapeutic Targets, Biomarkers, and Targetable Patient Subsets
Mr Alan Premasiri

DSP-21 At-Home Telespirometry (AHT) in Amyotrophic Lateral Sclerosis
Dr Eufrosina Young

COG-08 WITHDRAWN

COG-09 Screening for visuospatial abilities in amyotrophic lateral sclerosis: a pilot study using the Battery for Visuospatial Abilities (BVA)
Dr Minoo Sharbafshaaer

COG-10 People of Color living with and impacted by ALS and Community Created Intervention
Miss Katrina Byrd

COG-11 WITHDRAWN

CMS-18 Food Consumption of Individuals with Amyotrophic Lateral Sclerosis
Ms Maria Luisa do Nascimento Felipe

CMS-19 Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: An international survey
Mr Jochem Helleman

CMS-20 Bringing health care closer to patients – two years of the home care ALS programme in Slovenia
Dr Blaž Koritnik

CMS-21 A Telemedicine Approach to Goals of Care Discussions in Motor Neuron Disease
Mrs Paula Brockenbrough

CMS-22 ALS Community Support Assessment to Improve Online Access to Information and Resources in Italy
Mr Silverio Conte

CMS-23 Educommunication for food and nutrition in Amyotrophic Lateral Sclerosis
Sra Karla Coutinho

CMS-24 At-Home Telespirometry (AHT) in Amyotrophic Lateral Sclerosis (ALS): Digital Health Technology and Quality Control
Dr Bhavya Narapureddy

CMS-25 Eligibility, prescription, and dispensation of riluzole and Radicava(R) for newly diagnosed people with Amyotrophic Lateral Sclerosis (ALS): a single site retrospective chart review
Ms Kelsey Tymkow

Friday 9 December 2022

LIVE POSTER SESSION D

12.15 – 13. GMT

EPI-13 Time interval between age at retirement from soccer and the onset of ALS in the Spanish league: a literature review and meta-analysis.
Dr Josep Gamez

EPI-14 The influence of agricultural areas on ALS risk and phenotype: a population-based study
Dr Umberto Manera

EPI-15 Presymptomatic geographical distribution of patients with Amyotrophic Lateral Sclerosis: a population-based cluster analysis.
Dr Rosario Vasta

GEN-24 Reduced-penetrance Huntington's disease-causing alleles with 39 CAG trinucleotide repeats could be a genetic factor of amyotrophic lateral sclerosis
Dr Kangyang Jih

GEN-25 Discovering novel MND causal mutations through comprehensive assessment of complex genomic variant types
Dr Emily McCann

GEN-26 WITHDRAWN

GEN-27 Does familiarity for neurodegenerative diseases influence amyotrophic lateral sclerosis presentation? An exploratory clinical study.
Dr Marta Cillerai

GEN-28 Neuropeptide signalling processes perturbed in postmortem motor cortex of ALS patients
Dr Renata Kabiljo

GEN-29 Facilitating Template Structure Selection for in Silico Anaylses of ALS Proteins – A Comprehensive Dataset of All Available Experimentally Solved Wildtype and ALS Mutant Protein Structures
Miss Deborah Ness

GEN-30 WITHDRAWN

IVT-17 Developing a molecular platform for the rapid functional study of novel oligogenic MND candidate genes in vitro
Mx Sharlynn Wu

IVT-18 Human in vitro models of TDP-43 proteinopathy for drug screening approaches
Miss Valeria Casiraghi

IVT-19 DNA Damage Defects are Rescued by Enhancing Chromatin Ubiquitination and DDRNAs Biogenesis in ALS Cellular Model System
Dr Francesca Esposito

IVT-20 TDP-43 dysregulation and STMN-2 mis-splicing upon proteasomal inhibition in potential iPSC-derived neuronal ALS model
Dr Laila Ritsma

IVT-21 Investigating sporadic ALS using human iPSC-derived cells
Miss Lisha Ye

IVV-20 Hyperactivity of Purkinje cell and motor deficits in C9orf72 knockout mice
Dr Yuning Liu

IVV-21 Comparison of C9orf72 BAC mice on Jackson and Janvier FVB Backgrounds
Miss Sophie Badger

IVV-22 FUSDelta14 mutation impairs normal brain development and causes systemic metabolic alterations
Dr Silvia Corrochano

IVV-23 Disruption and phagocytosis of afferent synaptic terminals on axotomized spinal cord motor neurons: microglial recruitment and activation of necroptotic pathways
Miss Alaó Gatius

IVV-24 Characterisation of novel mouse models to investigate the involvement of inhibitory neurons in ALS and FTD linked to Fused in Sarcoma
Ms Felicie Lorenc

IVV-25 Re-modelling of the monosynaptic inputs to MCH neurons in SOD1G93A ALS murine model
Dr Jelena Scekic-Zahirovic

HCB-21 Divergent cerebellar transcriptome in amyotrophic lateral sclerosis cases with greater burden of pTDP-43 neuropathology
Ms Natalie Grima

HCB-22 Iron pathways are perturbed and accumulation overlaps with a shifted lipid profile in the CNS of human MND cases
Dr James Hilton

HCB-23 Cell autonomous dysfunction in VCP mutant hiPSC derived microglia
Dr Ben Clarke

HCB-24 Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models
Dr Yujing Gao

HCB-25 Single-Cell Proteomics and Lipidomics of Betz and Purkinje Cells in Human Motor Neuron Disease Brain
Miss Jasmine Reese

HCB-26 C9ORF72-ALS patient-derived iPSC microglia display pathological features associated with the hexanucleotide repeat expansion and have a pro-inflammatory profile
Dr Björn F. Vahsen

HCB-27 Meta-analysis of ALS astrocytes reveals inflammatory reactive states
Dr Oliver Ziff

BIO-15 TDP-43 accumulations within intramuscular nerve bundles of ALS patients
Dr Takashi Kurashige

BIO-16 WITHDRAWN

BIO-17 Extracellular Vesicle Sphingomyelins as Biomarkers in Amyotrophic Lateral Sclerosis
Dr Gavin McCluskey

BIO-18 Investigating the role of autoantibodies against Neurofilaments in neurodegeneration
Miss Ellie Sturmey

BIO-19 WITHDRAWN

TST-22 Targeting intracellular TDP-43 using SCFV'S vectorized to pegylated spions
Miss Yara Al Ojaimi

TST-23 Orexin-dependent sleep impairment in mouse models of ALS
Dr Simon J. Guillot

TST-24 Development of a methodology for the bio-synthesis of a novel "drug-like" cell-permeable peptide inhibiting the SRSF1-dependent nuclear export of C9ORF72-repeat transcripts in ALS/FTD
Mr Aytac Gul

TST-25 A novel "drug-like" therapeutic strategy to inhibit the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts in ALS/FTD
Dr Ya-Hui Lin

TST-26 The role of TUDCA in Neurodegeneration
Mrs Maria Lo Giudice

TST-27 Inhibition of class I histone deacetylases ameliorates TDP-43 pathology in experimental models of ALS
Dr Serena Scozzari

IMG-10 Cortical Hyperexcitability Associated Glutamate Abnormality in ALS
Dr Sicong Tu

IMG-11 Home-based electroencephalography in the assessment of cognitive decline in Amyotrophic Lateral Sclerosis and Fronto Temporal Dementia.
Dr Emmet Costello

IMG-12 Noradrenaline deficiency as a driver of cortical hyperexcitability in amyotrophic lateral sclerosis
Dr Caroline Rouaux

IMG-13 Exploring the split hand phenomenon with the neurophysiological index
Dr Cláudia Santos Silva

CLT-25 WITHDRAWN

CLT-26 Long term survival of participants in the mesenchymal stromal stem cells transplantation in amyotrophic lateral sclerosis.
Dr Fabiola De Marchi

CLT-27 Evaluation of the usability of the Atalante exoskeleton in the physical therapy of ALS patients
Mrs Ghida Trad

CLT-28 Estimating resting energy expenditure in people living with Amyotrophic Lateral Sclerosis
Ms Sarah Roscoe

CLT-29 A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients
Dr Giorgia Querin

DSP-22 miR-181 in plasma and CSF is a prognostic biomarker for ALS
Dr Iddo Magen

DSP-23 Interest of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis
Dr Hugo Alarcan

DSP-24 Brain metabolic changes due to sex differences in Amyotrophic Lateral Sclerosis (ALS): a 18F-FDG-PET study.
Dr Andrea Calvo

DSP-25 The role of peripheral immunity in Amyotrophic Lateral Sclerosis
Dr Maurizio Grassano

DSP-26 The flail-arm syndrome: the influence of phenotypic features
Dr Marta Gromicho

DSP-27 ALS and anxiety - a prognostic indicator?
Dr Mariam Kekenadze

DSP-28 Cognitive phenotypes in ALS relate to distinct longitudinal changes of functional 7networks disruption: a resting-state EEG study
Ms Marjorie Metzger

DSP-29 Evaluation of smartphone-based cough data in amyotrophic lateral sclerosis as a potential predictor functional disability
Mr Pedro Rocha

COG-12 The Italian version of the Hospital Anxiety and Depression Scale for use in Motor Neurone Disease (HADS-MND): detecting mood disorder in a large sample of MND patients
Dr Monica Consonni

COG-13 Apathy in Amyotrophic Lateral Sclerosis, and how it influences trial participation
MSc Juliette Foucher

COG-14 Italian adaptation of the Beaumont Behavioural Inventory (BBI): psychometric properties and clinical usability
Mrs Laura Peotta

COG-15 Stigma experienced by ALS patients and their caregivers: A mixed-methods study
Dr Marion Sommers-Spijkerman

COG-16 A systematic review of factors associated with grief in informal carers of people living with Motor Neurone Disease
Miss Ana Paula Trucco

CMS-26 Effects of e-learning as support communication for people with ALS among students in multiple healthcare disciplines: Assessment of single-session effects through pre- and post-tests.
Mr Tekemasa Ishikawa

CMS-27 Effect of Anti-aging therapies and cellular therapy a case of ALS
Dr Hemangi Sane

CMS-28 WITHDRAWN

CMS-29 Trends in the diagnostic delay and pathway for ALS patients across different countries
Dr Catarina Campos

CMS-30 When and why to withdraw riluzole?
Sr Jose Santiago Estevez Alonso

CMS-31 Real life experience with intrathecal tofersen. A case series.
Sra Maria Asunción Herrero Martin

CMS-32 Serum Chloride as marker and prognostic factor for respiratory failure in Amyotrophic Lateral Sclerosis patients
Dr. Enrico Matteoni

CMS-33 Recording of eye movements: an innovative source of clinical information in ALS
Miss Federica Cozza

13.45 – 14.00 BREAK

SESSION 8

NEUROINFLAMMATION

Chairs: A Malaspina (UK) and N Cole (UK)

PARALLEL SESSION

14.00 – 14.45 Parallel Session (non-CME)

14.00 – 14.20	**C21** Modelling neuroinflammation in ALS	*J Kriz (Canada)*
142.0 – 14.40	**C22** Suppressing Neuroinflammation: Regulatory T Lymphocyte Immunomodulatory Therapy for ALS	*S Appel (USA)*
14.40 – 14.55	**C23** Molecular signatures of neuroinflammation in patient tissue across sporadic, SOD1 and C9orf72 ALS cohorts	*O Rifai (UK)*
14.55 – 15.10	Discussion/Questions	

15.10 – 15.25 **BREAK**

SESSION 9

TRIAL DESIGN AND CLINICAL ENDPOINTS

Chairs: L Bruijn (UK) A Al-Chalabi (UK)

15.25 – 15.45	**C24** Improving clinical endpoints in therapeutic trials for ALS	*R van Eijk (Netherlands)*
15.45 – 16.05	**C25** Improving ALS clinical trial design	*T Ferguson/S Fradette (USA)*
16.05 – 16.20	**C26** Registry of Validated Endpoints in ALS (REVEALS): Results from a multi-centre prospective study of respiratory measures and their clinical meaningfulness	*D Meldrum (Ireland)*
16.20 – 16.35	Discussion/Questions	

16.35 – 16.50 **BREAK**

SESSION 10

CLOSING SESSION

Chairs: B Dickie (UK) A Al-Chalabi (UK)

16.50 – 16.55	Invitation to Basel 2023	
16.55 – 17.25	BrainGate: Clinical trials in intracortical brain-computer interfaces toward the restoration of communication and mobility	*L Hochberg (USA)*
17.25 – 17.35	Discussion/Questions	
17.35 – 17.55	Healey Center Prize and Lalji Family Award	
17.55 – 18.15	Final thoughts and Prize Draw	

Frequently Asked Questions (FAQ)

How do I login to the platform?
Approximately five days prior to the Symposium you will receive an email with your login details for the virtual platform, as well as instructions on how to login. We will also be sending out reminders on each morning of the Symposium. If you do have any issues logging into the virtual platform on the day, please use the 'Support' icon in the bottom righthand corner of the login page.

How do I update my contact details and sharing preferences?
Once you are signed into the virtual platform, you will be prompted to review and update your profile, photo and privacy settings. To choose what information you share in the meeting hub, scroll to the bottom of 'My Settings' and select the information you are happy to share with other attendees. If you would like to access this later, please click on your profile photo at the top right of the screen and select 'My Settings'.

How do I navigate the timeline?
Sessions and functions that are happening each day are listed in the timeline in chronological order. You can click on any of the items in the timeline to view session information and join the session or function. Once you are in a session, always use the 'Back to timeline' button to get back to the homepage.

What is the Meeting Hub?
The Meeting Hub allows you to connect and communicate with other attendees. Once you have found an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact with your connection by starting a live chat or live video call. You can also schedule to meet at a future time, send messages and take notes. Contact information for all attendees you have connected with be included when you export your contacts (see the Exporting your Notes and Contacts for additional information).

What is the Exhibitor Hall?
You can visit 'Exhibitor Hall' at any time of the day. Here, you can search and browse through the list of exhibitors. Clicking on the View Button lets you review the Exhibitor's Information and download any available brochures. You can also choose to connect with members of the Exhibitor team via Meeting Hub. If the exhibition is open and the exhibitor's staff are online, you can request a live meeting and you will be placed in a queue. You can always see your position in the queue and when you reach the top of the queue a video meeting with the selected member of the exhibitor's team will begin.

What is a Live Poster Session?
During the Live Poster Sessions, you will be able to browse and search for poster presentations that interest you. Click on the Poster Presentation to find out more information and enter to view the live presentation. When the presenter adds you to their presentation, your microphone will be unmuted. You can mute and unmute your microphone at any time if you wish to interact and ask the author questions.

Where do I go for technical support?
The quickest way to talk to us is by clicking on the red 'Support' icon in the top right of the screen. Our Support Team will be online and available to you.

What if I miss a session?
Don't worry if you miss a session, all sessions will be available to watch on-demand the day after they have aired until 8 March 2023.

Will I receive a certificate of attendance?
Certificates of attendance will be emailed to all delegates after the conference has ended.

EXHIBITORS

AMYLYX

Apellis

Biogen

brainstorm cell therapeutics

Cytokinetics

DENALI

ezekiel art

ferrer for good

Mitsubishi Tanabe Pharma

mnda motor neurone disease association

ZBiotech Zambon Biotech

With grateful thanks to the following supporters of the 33rd International Symposium on ALS/MND

PRINCIPAL SPONSOR

Cytokinetics

MAJOR SPONSORS

AMYLYX

Biogen

ferrer for good

brainstorm cell therapeutics

LifeArc Making life science life changing

KEY SPONSORS

Apellis

DENALI

Mitsubishi Tanabe Pharma

QurAlis

ZBiotech

GENERAL SPONSORS

ARG ATLANTIC RESEARCH GROUP

mnda motor neurone disease association

34th international symposium on ALS/MND

BASEL 2023

Join us in Basel, Switzerland

6 - 8 December 2023

Provisional abstract submission deadline:
Tuesday 11 July 2023

Stay connected:

mndresearch
#alsmndsymp

For further information please contact:

Motor Neurone Disease Association
Telephone: +44 (0) 1604 611837
Email: symposium@mndassociation.org
Email: abstracts@mndassociation.org

www.mndassociation.org
www.symposium.mndassociation.org